Table of Contents
An anti-cancer drug developed by GSK dramatically reduces patients’ risk of death, trials have shown.
The pharmaceutical giant’s Blenrep treatment was shown in a recent study to have reduced the risk of death by 42 percent in those suffering from multiple myeloma, a type of bone marrow cancer.
While the disease is still incurable, data showed that patients taking Blenrep would survive almost three years longer than those using existing treatments.
The results are a boost for GSK and its boss Emma Walmsley (pictured), who have been trying to improve the portfolio of new drugs and vaccines.
Blenrep could be worth more than £3bn in annual sales to GSK if it hits the market.
The drug has been accepted for priority review by Chinese regulators after a similar move last month by US regulators.
Trial success: GSK boss Emma Walmsley (pictured), who has been trying to improve the portfolio of new drugs and vaccines.
DIY INVESTMENT PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-to-use portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free Fund Trading and Investment Ideas
interactive inverter
interactive inverter
Fixed fee investing from £4.99 per month
sax
sax
Get £200 back in trading fees
Trade 212
Trade 212
Free trading and no account commission
Affiliate links: If you purchase a This is Money product you may earn a commission. These offers are chosen by our editorial team as we think they are worth highlighting. This does not affect our editorial independence.